Vaccines and microbicides preventing HIV-1, HSV-2, and HPV mucosal transmission

Journal of Investigative Dermatology

Volumn 130, Issue 2, 2010, Pages 352-361

  Nikolic, Damjan S ^a   Piguet, Vincent ^a  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ADENOVIRUS VECTOR; ADHESIVE AGENT; ALUMINUM HYDROXIDE; BACULOVIRUS VECTOR; CARRAGEENAN; CELLULOSE SULFATE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYANOVIRIN N; GLYCOPROTEIN D; GLYCOPROTEIN GD2; HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMIQUIMOD; MANDELIC ACID; MICROBICIDE; NONOXINOL 9; PRO 2000; RESIQUIMOD; TENOFOVIR; UNCLASSIFIED DRUG; VALACICLOVIR; VIVAGEL; WART VIRUS VACCINE;

ANTIBODY TITER; ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONDOM; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; GENITAL ULCER; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; LANGERHANS CELL; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SEXUAL TRANSMISSION; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VAGINA MUCOSA; VIRUS INFECTION; VIRUS LIKE AGENT; VIRUS REPLICATION; VIRUS TRANSMISSION; WART VIRUS;

EID: 75549087128     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.227     Document Type: Note

References (129)

1. Abbo L, Vincek V, Dickinson G, Shrestha N, Doblecki S, Haslett PA (2007) Selective defect in plasmacyoid dendritic cell function in a patient with AIDS-associated atypical genital herpes simplex vegetans treated with imiquimod. Clin Infect Dis 44:e25-7
2. Abbott A, Brumfiel G (2008) Nobel for AIDS virus discovery, finally. Nature 455:712-713
3. Alliance for Microbicide Development. http://secure.microbicide.org/ DesktopDefault.aspx? tabindex=0&tabid=1
4. Arbyn M, Raifu AO, Autier P, Ferlay J (2007) Burden of cervical cancer in Europe: estimates for 2004. Ann Oncol 18:1708-1715 (Pubitemid 47506260)
5. Arrighi JF, Pion M, Garcia E, Escola JM, van Kooyk Y, Geijtenbeek TB et al. (2004) DC-SIGN-mediated infectious synapse formation enhances X4 HIV-1 transmission from dendritic cells to T cells. J Exp Med 200:1279-1288
6. Asgari MM, Kiviat NB, Critchlow CW, Stern JE, Argenyi ZB, Raugi GJ et al. (2008) Detection of human papillomavirus DNA in cutaneous squamous cell carcinoma among immuno-competent individuals. J Invest Dermatol 128:1409-1417
7. Bakri Y, Schiffer C, Zennou V, Charneau P, Kahn E, Benjouad A et al. (2001) The maturation of dendritic cells results in postintegration inhibition of HIV-1 replication. J Immunol 166:3780-3788
8. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W et al. (2000) Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (New York, NY) 290:486-492
9. Bird KD (1991) The use of spermicide containing nonoxynol-9 in the prevention of HIV infection. AIDS (London, England) 5:791-796
10. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D et al. (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881-1893
11. Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, Schiller JT (2006) Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathog 2:e69
12. Carter JJ, Madeleine MM, Shera K, Schwartz SM, Cushing-Haugen KL, Wipf GC et al. (2001) Human papillomavirus 16 and 18 L1 serol-ogy compared across anogenital cancer sites. Cancer Res 61:1934-1940
13. Casimiro DR, Wang F, Schleif WA, Liang X, Zhang ZQ, Tobery TW et al. (2005) Attenuation of simian immunodeficiency virus SIV-mac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J Virol 79:15547-15555
14. Catanzaro AT, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z et al. (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 194:1638-1649
15. Cavrois M, Neidleman J, Kreisberg JF, Fenard D, Callebaut C, Greene WC (2006) Human immunodeficiency virus fusion to dendritic cells declines as cells mature. J Virol 80: 1992-1999
16. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S et al. (2008) Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. Lancet 371:2109-2119
17. Chege GK, Shephard EG, Meyers A, van Harme-len J, Williamson C, Lynch A et al. (2008) HIV-1 subtype C Pr55gag virus-like particle vaccine efficiently boosts baboons primed with a matched DNA vaccine. J Gen Virol 89:2214-2227
18. Cheshenko N, Keller MJ, MasCasullo V, Jarvis GA, Cheng H, John M et al. (2004) Candidate topical microbicides bind herpes simplex virus glycoprotein B and prevent viral entry and cell-to-cell spread. Antimicrob Agents Chemother 48:2025-2036
19. Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S et al. (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366:991-998
20. Cohen J (2009) Retrovirus meeting. HIV/AIDS researchers reach for high-hanging fruit. Science (New York, NY) 323:996-997
21. Corey L (2007) Synergistic copathogens\-HIV-1 and HSV-2. New Engl J Med 356:854-856
22. Corey L, Langenberg AG, Ashley R, Sekulovich RE, Izu AE, Douglas JM Jr et al. (1999) Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282:331-340
23. Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T et al. (2004) Once-daily valacy-clovir to reduce the risk of transmission of genital herpes. New Engl J Med 350:11-20
24. Cranage M, Sharpe S, Herrera C, Cope A, Dennis M, Berry N et al. (2008) Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-ex-posure application of tenofovir gel. PLoS Med 5:e157; discussion e157
25. D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM et al. (2007) Case-control study of human papillomavirus and oropharyngeal cancer. New Engl J Med 356:1944-1956 (Pubitemid 46740304)
26. de Witte L, Nabatov A, Pion M, Fluitsma D, de Jong MA, de Gruijl T et al. (2007) Langerin is a natural barrier to HIV-1 transmission by Langerhans cells. Nat Med 13:367-371
27. Denton PW, Estes JD, Sun Z, Othieno FA, Wei BL, Wege AK et al. (2008) Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med 5:e16
28. Devitt G, Emerson V, Holtkotte D, Pfeiffer T, Pisch T, Bosch V (2007) Incorporation of chimeric HIV-SIV-Env and modified HIV-Env proteins into HIV pseudovirions. Virology 361:465-471
29. Dorrell L, Williams P, Suttill A, Brown D, Roberts J, Conlon C et al. (2007) Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine 25:3277-3283
30. Durst M, Gissmann L, Ikenberg H, zur Hausen H (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80:3812-3815
31. Emini EA, Schleif WA, Nunberg JH, Conley AJ, Eda Y, Tokiyoshi S et al. (1992) Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 355:728-730
32. Fichorova RN, Tucker LD, Anderson DJ (2001) The molecular basis of nonoxynol-9-induced vaginal inflammation and its possible relevance to human immunodeficiency virus type 1 transmission. J Infect Dis 184:418-428
33. Fischetti L, Barry SM, Hope TJ, Shattock RJ (2009) HIV-1 infection of human penile explant tissue and protection by candidate micro-bicides. AIDS 23:319-328
34. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF (2005) Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191:654-665
35. Freeman EE, Weiss HA, Glynn JR, Cross PL, Whitworth JA, Hayes RJ (2006) Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies. AIDS 20:73-83
36. FUTURE (2007) Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New Engl J Med 356:1915-1927
37. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S et al. (2008) Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med 5: e28
38. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al. (2007) Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New Engl J Med 356:1928-1943 (Pubitemid 46740303)
39. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J et al. (2000) DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100:587-597
40. Gilbert PB, Chiu YL, Allen M, Lawrence DN, Chapdu C, Israel H et al. (2003) Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 21:2933-2947
41. Gilbert PB, Peterson ML, Follmann D, Hudgens MG, Francis DP, Gurwith M et al. (2005) Correlation between immunologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 191:666-677 (Pubitemid 40271053)
42. Giroglou T, Florin L, Schafer F, Streeck RE, Sapp M (2001) Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75:1565-1570
43. Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z et al. (2006) Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194:1650-1660
44. Granelli-Piperno A, Delgado E, Finkel V, Paxton W, Steinman RM (1998) Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M-and T-tropic virus to T cells. J Virol 72:2733-2737
45. Granelli-Piperno A, Shimeliovich I, Pack M, Trumpfheller C, Steinman RM (2006) HIV-1 selectively infects a subset of nonmaturing BDCA1-positive dendritic cells in human blood. J Immunol 176:991-998
46. Grant RM, Hamer D, Hope T, Johnston R, Lange J, Lederman MM et al. (2008) Whither or wither microbicides? Science (New York, NY) 321:532-534
47. Gregson S, Nyamukapa C, Lopman B, Mushati P, Garnett GP, Chandiwana SK et al. (2007) Critique of early models of the demographic impact of HIV/AIDS in sub-Saharan Africa based on contemporary empirical data from Zimbabwe. Proc Natl Acad Sci US Am 104:14586-14591
48. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM et al. (2006) Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367:1247-1255
49. Herold BC, Scordi-Bello I, Cheshenko N, Marcel-lino D, Dzuzelewski M, Francois F et al. (2002) Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry. J Virol 76: 11236-11244
50. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC et al. (2007) Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298:743-753
51. Hladik F, McElrath MJ (2008) Setting the stage: host invasion by HIV. Nat Rev Immunol 8:447-457
52. Hladik F, Sakchalathorn P, Ballweber L, Lentz G, Fialkow M, Eschenbach D et al. (2007) Initial events in establishing vaginal entry and infection by human immunodeficiency virus type-1. Immunity 26:257-270
53. Hu J, Gardner MB, Miller CJ (2000) Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J Virol 74:6087-6095
54. Hu Q, Frank I, Williams V, Santos JJ, Watts P, Griffin GE et al. (2004) Blockade of attachment and fusion receptors inhibits HIV-1 infection of human cervical tissue. J Exp Med 199:1065-1075
55. Ismaili J, Rennesson J, Aksoy E, Vekemans J, Vincart B, Amraoui Z et al. (2002) Monopho-sphoryl lipid A activates both human dendritic cells and T cells. J Immunol 168:926-932
56. Kawamura T, Cohen SS, Borris DL, Aquilino EA, Glushakova S, Margolis LB et al. (2000) Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med 192:1491-1500
57. Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM et al. (2003) R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci USA 100:8401-8406
58. Kawamura T, Qualbani M, Thomas EK, Orenstein JM, Blauvelt A (2001) Low levels of productive HIV infection in Langerhans cell-like dendritic cells differentiated in the presence of TGF-beta1 and increased viral replication with CD40 ligand-induced maturation. Eur J Immunol 31:360-368
59. Keller MJ, Zerhouni-Layachi B, Cheshenko N, John M, Hogarty K, Kasowitz A et al. (2006) PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis 193: 27-35
60. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT (1992) Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89:12180-12184
61. Kran AM, Sorensen B, Sommerfelt MA, Nyhus J, Baksaas I, Kvale D (2006) Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells. AIDS (London, England) 20:627-630
62. Kreuter A, Potthoff A, Brockmeyer NH, Gambich-ler T, Stucker M, Altmeyer P et al. (2008) Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. J Invest Dermatol 128:2078-2083
63. Kuhmann SE, Hartley O (2008) Targeting chemo-kine receptors in HIV: a status report. Annu Rev Pharmacol Toxicol 48:425-461
64. Lacey CJ, Lowndes CM, Shah KV (2006) Chapter 4: burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 24(Suppl 3):S3/35-41
65. Langenberg AG, Corey L, Ashley RL, Leong WP, Straus SE (1999) A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. New Engl J Med 341:1432-1438
66. Li et al. (2009) Nature. Advanced online pub-lication:doi:10.1038/ nature07831
67. Lingappa JR, Kahle E, Mugo N, Mujugira A, Magaret A, Baeten J et al. (2009) Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS ONE 4:e5272
68. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM et al. (2009) Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457:87-91
69. Looker KJ, Garnett GP, Schmid GP (2008) An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 86:805-812
70. Lore K, Smed-Sorensen A, Vasudevan J, Mascola JR, Koup RA (2005) Myeloid and plasmacy-toid dendritic cells transfer HIV-1 preferentially to antigen-specific CD4+ T cells. J Exp Med 201:2023-2033
71. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D (2003) Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103
72. Mark KE, Corey L, Meng TC, Magaret AS, Huang ML, Selke S et al. (2007) Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J Infect Dis 195:1324-1331
73. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D et al. (1999) Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73:4009-4018
74. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH et al. (1996) Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 173:340-348
75. Mayer KH, Karim SA, Kelly C, Maslankowski L, Rees H, Profy AT et al. (2003) Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS (London, England) 17:321-329
76. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A et al. (2006) Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS (London, England) 20:543-551
77. McDonald D, Wu L, Bohks SM, KewalRamani VN, Unutmaz D, Hope TJ (2003) Recruitment of HIV and its receptors to dendritic cell-T cell junctions. Science (New York, NY) 300:1295-1297
78. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H et al. (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:1894-1905
79. Mesquita PM, Wilson SS, Manlow P, Fischetti L, Keller MJ, Herold BC et al. (2008) Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model. J Virol 82:6576-6584
80. Nagot N, Ouedraogo A, Foulongne V, Konate I, Weiss HA, Vergne L et al. (2007) Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. New Engl J Med 356:790-799
81. Ogawa Y, Kawamura T, Kimura T, Ito M, Blauvelt A, Shimada S (2009) Gram positive bacteria enhance HIV-1 susceptibility in Langerhans cells, but not in dendritic cells, via TLR activation. Blood 113:5157-5166
82. Ouedraogo A, Nagot N, Vergne L, Konate I, Weiss HA, Defer MC et al. (2006) Impact of suppressive herpes therapy on genital HIV-1 RNA among women taking antiretroviral therapy: a randomized controlled trial. AIDS (London, England) 20:2305-2313
83. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM et al. (2007) Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369:2161-2170
84. Palliser D, Chowdhury D, Wang QY, Lee SJ, Bronson RT, Knipe DM et al. (2006) An siRNA-based microbicide protects mice from lethal herpes simplex virus 2 infection. Nature 439:89-94
85. Patel AS, Karagas MR, Perry AE, Nelson HH (2008) Exposure profiles and human papillo-mavirus infection in skin cancer: an analysis of 25 genus beta-types in a population-based study. J Invest Dermatol 128:2888-2893
86. Patterson S, Rae A, Hockey N, Gilmour J, Gotch F (2001) Plasmacytoid dendritic cells are highly susceptible to human immunodeficiency virus type 1 infection and release infectious virus. J Virol 75:6710-6713
87. Perreau M, Pantaleo G, Kremer EJ (2008) Activation of a dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 205:2717-2725
88. Peters BS, Jaoko W, Vardas E, Panayotakopoulos G, Fast P, Schmidt C et al. (2007) Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immuno-genicity. Vaccine 25:2120-2127
89. Phillips DM, Zacharopoulos VR (1998) Nonox-ynol-9 enhances rectal infection by herpes simplex virus in mice. Contraception 57: 341-348
90. Piguet V, Blauvelt A (2002) Essential roles for dendritic cells in the pathogenesis and potential treatment of HIV disease. J Invest Dermatol 119:365-369
91. Piguet V, Steinman RM (2007) The interaction of HIV with dendritic cells: outcomes and pathways. Trends Immunol 28:503-510
92. Pion M, Arrighi JF, Jiang J, Lundquist CA, Hartley O, Aiken C et al. (2007a) Analysis of HIV-1-X4 fusion with immature dendritic cells identifies a specific restriction that is independent of CXCR4 levels. J Invest Dermatol 127:319-323
93. Pion M, Granelli-Piperno A, Mangeat B, Stalder R, Correa R, Steinman RM et al. (2006) APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection. J Exp Med 203:2887-2893
94. Pion M, Stalder R, Correa R, Mangeat B, Towers GJ, Piguet V (2007b) Identification of an arsenic-sensitive block to primate lentiviral infection of human dendritic cells. J Virol 81:12086-12090
95. Plotkin SA (2001) Immunologic correlates of protection induced by vaccination. Pediatr Infect Dis J 20:63-75
96. Pope M, Betjes MG, Romani N, Hirmand H, Cameron PU, Hoffman L. et al. (1994) Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1. Cell 78:389-398
97. Pope M, Gezelter S, Gallo N, Hoffman L, Stein-man RM (1995) Low levels of HIV-1 infection in cutaneous dendritic cells promote extensive viral replication upon binding to memory CD4\+ T cells. Exp Med 182:2045-2056
98. Roberts JN, Buck CB, Thompson CD, Kines R, Bernardo M, Choyke PL et al. (2007) Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 13:857-861
99. Rupp R, Rosenthal SL, Stanberry LR (2007) VivaGel (SPL7013 Gel): a candidate dendri-mer\-microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine 2:561-566
100. Rusconi S, Moonis M, Merrill DP, Pallai PV, Neidhardt EA, Singh SK et al. (1996) Naphthalene sulfonate polymers with CD4-blocking and anti-human immunodeficiency virus type 1 activities. Antimicrob Agents Chemother 40:234-236
101. Schacker T, Ryncarz AJ, Goddard J, Diem K, Shaughnessy M, Corey L (1998) Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. JAMA 280:61-66
102. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J et al. (2009) Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640
103. Seth A, Ourmanov I, Schmitz JE, Kuroda MJ, Lifton MA, Nickerson CE et al. (2000) Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J Virol 74:2502-2509
104. Sheehy AM, Gaddis NC, Choi JD, Malim MH (2002) Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650
105. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S et al. (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science (New York, NY) 284:1835-1837
106. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B et al. (2008) Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 372:1977-1987
107. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R et al. (2007) Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 121:621-632
108. Sobngwi-Tambekou J, Taljaard D, Lissouba P, Zarca K, Puren A, Lagarde E et al. (2009) Effect of HSV-2 serostatus on acquisition of HIV by young men: results of a longitudinal study in Orange Farm, South Africa. J Infect Dis 199:958-964
109. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S et al. (2002) Glycoprotein-D-adjuvant vaccine to prevent genital herpes. New Engl J Med 347:1652-1661
110. Stremlau M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J (2004) The cytoplas-mic body component TRIM5alpha restricts HIV-1 infection in Old World monkeys. Nature 427:848-853
111. Teleshova N, Chang T, Profy A, Klotman ME (2008) Inhibitory effect of PRO 2000, a candidate microbicide, on dendritic cell-mediated human immunodeficiency virus transfer. Antimicrob Agents Chemother 52:1751-1758
112. Trottier S, Omar RF, Desormeaux A, Drouin J, Gagnon MT, Vezina F et al. (2007) Safety, tolerance and acceptability of the Invisible Condom and its vaginal applicator in healthy women and their male sexual partners. Contraception 76:117-125
113. Tsai CC, Emau P, Jiang Y, Agy MB, Shattock RJ, Schmidt A et al. (2004) Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 20:11-18
114. Tschachler E, Groh V, Popovic M, Mann DL, Konrad K, Safai B et al. (1987) Epidermal Langerhans cells\-a target for HTLV-III/LAV infection. J Invest Dermatol 88:233-237
115. UNAIDS. http:www.unaids.org/en/default.asp
116. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML et al. (2008) Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. New Engl J Med 359:463-472
117. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H et al. (2002) Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 360:971-977
118. Van Rompay KK, Kearney BP, Sexton JJ, Colon R, Lawson JR, Blackwood EJ et al. (2006) Evaluation of oral tenofovir disoproxil fuma-rate and topical tenofovir GS-7340 to protect infant macaques against repeated oral challenges with virulent simian immunodeficiency virus. J Acquir Immune Defic Syndr 43:6-14
119. Van Rompay KK, Schmidt KA, Lawson JR, Singh R, Bischofberger N, Marthas ML (2002) Topical administration of low-dose tenofovir disoproxil fumarate to protect infant macaques against multiple oral exposures of low doses of simian immunodeficiency virus. J Infect Dis 186:1508-1513
120. Wald A, Langenberg AG, Krantz E, Douglas JM Jr, Handsfield HH, DiCarlo RP et al. (2005) The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 143:707-713
121. Wang BZ, Liu W, Kang SM, Alam M, Huang C, Ye L et al. (2007) Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J Virol 81:10869-10878 (Pubitemid 47536061)
122. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC (2008) Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 14:617-621
123. Watson-Jones D, Weiss HA, Rusizoka M, Changalucha J, Baisley K, Mugeye K et al. (2008) Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. New Engl J Med 358: 1560-1571
124. Williams DL, Newman DR, Ballagh SA, Creinin MD, Barnhart K, Weiner DH et al. (2007) Phase I safety trial of two vaginal microbicide gels (Acidform or BufferGel) used with a diaphragm compared to KY jelly used with a diaphragm. Sex Transm Dis 34:977-984
125. Witcher KJ, Novick RP, Schlievert PM (1996) Modulation of immune cell proliferation by glycerol monolaurate. Clin Diagn Lab Immunol 3:10-13
126. Zambruno G, Mori L, Marconi A, Mongiardo N, De Rienzo B, Bertazzoni U et al. (1991) Detection of HIV-1 in epidermal Langerhans cells of HIV-infected patients using the polymerase chain reaction. J Invest Dermatol 96:979-982
127. Zhou J, Sun XY, Stenzel DJ, Frazer IH (1991) Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185:251-257
128. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737
129. Zur Hausen H (2009) Papillomaviruses in the causation of human cancers\-a brief historical account. Virology 384:260-265